Basic Study

Expression of annexin II in gastric carcinoma and its role in gastric cancer metastasis

Feng Han, Shikha Shrestha, Hua Huang, Huang-Yong Lv, Chuan Nie, Ling Lin, Ming-Liang Lu

Author contributions: Lu ML and Huang H designed the research, and controlled the structure and quality of the paper; Han F and Shrestha S proposed the study and collected and analyzed the data, and wrote the first draft; Lv Hy, Nie C and Lin L enriched and improved the discussion section.

Institutional review board statement: The medical records and research data of the subjects are kept confidential. When the results are published, Information related to the subject will not be disclosed. The research program meets the medical ethics. The research topic is ethical.

Conflict-of-interest statement: All the authors have no conflicts of interests to declare.

Data sharing statement: No additional unpublished data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Abstract

AIM
To investigate the expression of annexin II in gastric carcinoma and its role in the metastasis of gastric cancer.

METHODS
The expression of annexin II in 51 cases of gastric carcinoma and 24 cases of adjacent tissues was detected by immunohistochemistry. The relationship between annexin II and clinical features of gastric cancer was analyzed. Annexin II specific siRNA was used to inhibit the expression of annexin II in gastric cancer HGC-27 cells, and the effects of annexin II on the migration and secretion of matrix metalloproteinases (MMPs) were observed.

RESULTS
The positive rate of annexin II protein was 82.4% in gastric cancer tissues and 37.5% in adjacent tissues. There was significant difference between the two groups ($P < 0.01$); and the positive expression of annexin II was not related to the sex and age of the patients ($P > 0.05$). The expression of annexin II...
In this study, we retrospectively analyzed Annexin II expression in gastric cancer tissues, and the expression was significantly correlated with tumor size, histological differentiation, TNM stage, lymph node metastasis, and other clinical features. The difference was statistically significant ($P < 0.05$). Inhibition of annexin II expression in gastric cancer cells led to decreased migration and secretion of matrix metalloproteinases (MMPs), which was statistically significant ($P < 0.05$).

CONCLUSION
Annexin II is highly expressed in gastric cancer tissues. The expression of annexin II protein is related to tumor size, histological differentiation, TNM staging, lymph node metastasis, and other clinical features. Annexin II high expression can promote the invasion and metastasis of gastric cancer.

Key words: Gastric cancer; Annexin II; Metastasis; Real-time quantitative PCR; Human gastric cancer; HGC-27 cells; Matrix metalloproteinases

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In this study, we retrospectively analyzed the expression of annexin II in 51 cases of gastric carcinoma and 24 cases of adjacent tissue to investigate the relationship between the positive expression of annexin II and the invasion and metastasis of gastric cancer.

INTRODUCTION
Gastric cancer is one of the most common malignancies in my country, the first in the digestive tract malignant tumor, ranking the fourth in the world[1]. Because of its symptoms hidden, the disease developed rapidly, when diagnosed in the late period, the treatment effect is often poor, a serious threat to human health, but the early treatment of gastric cancer is good, 5 years after radical resection rate of up to 90% or more, So in-depth study of the occurrence and development of gastric cancer mechanism, For the prognosis of gastric cancer and the treatment of gastric cancer has a very important clinical significance.

Annexin II is a calcium-dependent phospholipid-binding protein. Mainly in the form of monomer, dimer, and tetramer, the study showed[2-6]: Annexin II are highly expressed in liver cancer, breast cancer, colon cancer, lung cancer and other malignant tumors, And play an important role in the occurrence, development and infiltration of tumor. In this study, the expression of annexin II in 51 cases of gastric carcinoma and 24 cases of adjacent tissues was detected by immunohistochemistry, to investigate the relationship between the positive expression of annexin II and the clinical characteristics of gastric cancer. And annexin II specific siRNA was used to inhibit the expression of annexin II in gastric cancer HGC-27 cells, Detection of cell adhesion, invasion, migration, matrix metalloproteinases (MMPs) secretion and other capacity changes.

MATERIALS AND METHODS

Materials
Fifty-one cases of surgical specimens of gastric cancer were collected during the period from January 2012 to June 2014, among them, 30 males and 21 females; aged 32-78 years, mean age 58.6 ± 3.2 years; the above cases were not treated before radiotherapy, chemotherapy and other anti-tumor therapy. From the above 51 cases of gastric cancer, twenty-four patients were randomly selected from the normal tissue of the stomach. All specimens were fixed with formaldehyde, Paraffin embedded, sliced. Gastric cancer HGC-27 cells were purchased from the Shanghai Institute of Biochemistry and Cell Biology. Study has been reviewed by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in an appropriate version of the Declaration of Helsinki. All persons gave their informed consent prior to their inclusion in the study.

Methods

Immunohistochemical staining: Annexin II antibody was purchased from Abcam Reagent Company; Immunohistochemistry kit, DAB kit was purchased from Pikiton Reagent Company. Sliced was kept in high temperature and high pressure tissue antigen repair. The dyeing step is carried out according to the kit instructions. Positive plates were used as positive control, PBS instead of primary antibody as a negative control. The results showed that annexin II positive expression of brown matter in the cytoplasm appears brown matter. Each slice 5 representative of the high power field, Each field count 100 cells, The percentage of positive cells and the intensity of staining were scored separately. Specific criteria are as follows: (1) according to the degree of staining score: no staining for 0 points, Dyeing strength is 1 point; Medium dyeing intensity of 2 points; Strong staining intensity of 3 points. (2) Score according to the percentage of colored cells: The percentage of cells in the stained cells was < 5% for 0 points, 5%-25% for 1 points, 26%-50% for 2 points, 51%-75% for 3 points, > 75% for 4 points. (1) + (2) for the total points. The total score of 0-7 points. 0 is negative (-),
1-2 is divided into weak positive (+), 3-5 are divided into positive (++), 6-7 is divided into strong positive (+++).

**Cell culture:** Gastric cancer HGC-27 cells were cultured in RPMI1640 cell culture medium containing 10% fetal bovine serum and cultured in 5% CO₂, 37 °C, saturated cell culture incubator.

**Cell transfection:** Gastric cancer HGC-27 cells (1 × 10⁶ cells/mL) were seeded in 24-well plates, cultured overnight at 37 °C, 5% CO₂ and saturated humidity. Serum-free medium wash cells, 1 μL (20 pmol) of Annexin II siRNA was dissolved in 49 μL serum-free medium, 1 μL of liposomes was dissolved in 59 μL of serum-free medium, After keeping at room temperature for 10 min, Mix the two type of liquids, room temperature for 20 min. The mixture was then added to the 24-well plate of the cells to be transfected, Add serum-free medium to 500 μL, Placed in 37 °C, 5% CO₂ cell incubator culture, 6 h later replaced with 10% newborn bovine serum RPMI1640 medium.

**Real-time quantitative PCR:** Use Trizol method to extract total RNA from cells, The total RNA samples of the extracted osteoblasts were reverse transcribed into cDNA, Using the following reaction system: 2 μg template RNA, 1 μL oligo dT primer, 2 μL dNTP mixture, 1 μL Ace reverse transcriptase, 1 μL RNase inhibitor, 4 μL 5 × RT buffer, 10 μL RNase-free water. The reaction conditions were as follows: first step 37 °C 30 min, The second step is 84 °C for 30 s. The reaction product was stored at 4 °C. And then real-time quantitative PCR reaction. Using the following reaction system: 12.5 μL Real Master Mix (SYBR I), 2 μL template cDNA, 1 μL forward primer, 1 μL reverse primer, 8.5 μL RNase-free water. The reaction conditions are: first step 94 °C 5 min; second step 94 °C 60 s, 57 °C 30 s, 72 °C 30 s, a total of 30 cycles; the third step 72 °C 5 min; the last 4 °C end of the reaction. The experimental data were analyzed by Option Monitor V3.1 software of real-time PCR.

**Cell invasion experiment:** A 1:3 diluted matrigel (RPMI 1640 dilution) was added to the matrigel invasion chamber, 37 °C for 2 h, 2 × 10⁶ gastric cancer cells were resuspended in 0.1% fetal bovine serum culture medium and inoculated in the chamber, RPMI 1640 medium containing 10% fetal bovine serum was added to the 24-well plate of the lower chamber, 37 °C for 24 h. Remove the invasion chamber, With a cotton swab gently wipe the room did not pass through the cells, formaldehyde fixed for 10 min, Hematoxylin-eosin staining, Cut the filter, the neutral gum seal, light microscopy count the number of cells through the membrane. The number of cells in the membrane was calculated by taking 10 fields under light microscope. Each independent experiment was repeated three times.

**Cell migration experiments:** First with a marker pen in the 6-well plate even behind a horizontal line, Cross through the hole. About 2 × 10⁶ gastric cancer cells were seeded in 6-well plates when the cells are completely fused, the tip of the nose is as far as possible to the horizontal line behind the horizontal scratches. Wash the cells three times with PBS, wash off the cells under the cells, and then add serum-free medium. And incubated in a CO₂ incubator at 37 °C, 0 and 24 h under inverted microscope to observe and take pictures. The scribe width was measured with Image J software and the cell mobility was calculated. Cell mobility = (0 h scratch width - 24 h scratch width)/0 h scratch width × 100%. Each independent experiment was repeated three times.

**Cell gelatin zymography experiments:** Cells were treated with annexin II siRNA Digest the cells and count, the corresponding conditioned medium was collected, 1500 g low-speed centrifugation 10 min after removal of cell debris, Take the supernatant 4 °C spare. And then take the protein quality samples separately with non-reduction Loading Buffer Homogeneously mixed, incubated at 55 °C for 5 min. Prepare 5% concentrated gum and 8% separated gel containing 0.1% gelatin. Constant pressure electrophoresis until the edge of bromophenol blue separation from the front of the separation of about 0.5 cm. The gel was removed and transferred to the elution solution, eluting twice every 30 min. Rinse with gelatin incubation once, and then placed in gelatin incubation buffer at 37 °C for 18 h. Dyeing solution 4 h After the rinsing of distilled water, And then take a photo by a gel image analyzer.

**Statistical analysis**
Each independent experiment was repeated more than three times. Student-t test was performed with SPSS 16.0 software, the results are expressed as mean ± SD, qualitative data were compared using χ² test, P < 0.05 indicating that the difference was statistically significant.

**RESULTS**

**Expression of annexin II Protein in gastric carcinoma and its relationship with clinical characteristics of gastric cancer**

**Expression of AnnexinII in gastric carcinoma and adjacent tissues:** Annexin II protein positive expression of cytoplasm in the yellow granular material, Mainly located in the cytoplasm (Figure 1). In 51 cases of gastric cancer, 42 cases were positive, The positive rate was 82.4% of which strong positive in 3 cases, Positive in 12 cases, Weakly positive in 27 cases, Negative in 9 cases. In 24 cases of
Effect of annexin II on the migration ability of gastric cancer cells: Scaling experiments were performed to detect changes in cell migration ability. Compared with the control group transfected with Control siRNA, the migration ability of human gastric cancer HGC-27 cells transfected with Annexin II siRNA was significantly decreased, differences were statistically significant ($P < 0.01$; figure 3).

Effect of annexin II on secretion of MMPs in gastric cancer cells: The changes of MMPs secretion were detected by gelatin zymography. Compared with the control group transfected with Control siRNA, Human gastric cancer HGC-27 cells transfected with AnnexinII siRNAs after MMPs secretion was significantly reduced, Differences were statistically significant ($P < 0.01$; figure 4).

### Expression of annexin II protein in patients with clinical characteristics of gastric cancer:

The study found, annexin II positive expression was not related to the sex of the patient ($P > 0.05$) while annexin II protein expression was associated with tumor size, histological differentiation, TNM staging, lymph node metastasis and other clinical features were significantly correlated, the difference was statistically significant ($P < 0.05$, Table 2).

| Group         | n  | Annexin II protein | Positive rate, $P$ value |
|---------------|----|--------------------|--------------------------|
| Gastric cancer| 51 | - 9, + 27, ++ 12, +++ 3 | 82.4                     |
| Paracancerous | 24 | - 15, + 6, ++ 3, +++ 0 | 37.5, $<0.01$            |

### Table 1 Expression of annexin II protein in gastric carcinoma and paracancerous tissues

| Group         | $n$ | Annexin II | Positive, $P$ value |
|---------------|-----|------------|---------------------|
| Gastric cancer| 51  | - 9, + 27, ++ 12, +++ 3 | 82.4 |
| Paracancerous | 24  | - 15, + 6, ++ 3, +++ 0 | 37.5, $<0.01$ |

### Table 2 Relationship between annexin II protein and clinical characteristics of gastric cancer patients

| Group         | $n$ | Annexin II positive | Positive rate, $P$ value |
|---------------|-----|---------------------|--------------------------|
| Age in yr     |     |                     |                          |
| $< 60$        | 27  | 23                  | 85.2, $>0.05$            |
| $> 60$        | 24  | 19                  | 79.2                     |
| Sex           |     |                     |                          |
| Male          | 31  | 27                  | 87.1, $>0.05$            |
| Female        | 20  | 15                  | 75.0                     |
| Tumor diameter in cm | 19 | 12                  | 63.2, $<0.05$            |
| $> 5$         | 32  | 30                  | 93.8                     |
| Differentiation|     |                     |                          |
| Well differentiated | 15 | 9                  | 60.0, $<0.05$            |
| Poorly differentiated | 36 | 33                 | 91.7                     |
| Clinical stage|     |                     |                          |
| I + II period | 17  | 10                  | 58.8, $<0.05$            |
| III + IV period | 34 | 32                 | 94.1                     |
| Lymph node metastasis |     |                     |                          |
| Have          | 33  | 31                  | 93.9, $<0.05$            |
| Not have      | 18  | 11                  | 61.1                     |

### The role of annexin II in gastric cancer metastasis

**SiRNA inhibits annexin II expression:** The siRNA fragment targeting annexin II was transfected into human gastric cancer HGC-27 cells, the mRNA and protein expression of annexin II in human gastric cancer HGC-27 cells were detected by real-time PCR and Western blot after 24 h. And transfected unrelated interfering siRNA fragments (control siRNA) as a negative control. The results show, annexin II siRNA can significantly inhibit the transcription and protein expression of annexin II mRNA in human gastric cancer HGC-27 cells, the difference was statistically significant ($P < 0.05$; figure 2).
DISCUSSION

Annexins is a class of calcium-dependent phospholipid-binding proteins, which are widely present in the cell membrane, cytoplasmic or extracellular matrix. There are two basic functional domains on the structure: Highly conserved C-terminal core regions and highly variable N-terminal domains. The former has a binding site of $\text{Ca}^{2+}$ and membrane, in the form of calcium-dependent reversible binding to cell membrane phospholipids, the latter determines annexins specific biological functions. Annexins participate in a series of activities of cells, such as endocytosis, exocytosis, cell proliferation, differentiation and apoptosis, and cytoskeleton activity, signal transduction and etc\cite{7}. Annexin II as a member of the annexins family A subfamily, Also known as p36, AXA2, LIP2, etc. Its gene is located in 15q21-q22, containing 1.4 kb encoding gene\cite{8,9}.

In this study, the expression of annexin II in gastric...
cancer tissues and adjacent tissues was analyzed. The results showed that the expression of annexin II protein in gastric cancer tissues was significantly higher than that in adjacent tissues. To analyze the correlation between the expression of annexin II protein and the clinical characteristics of gastric cancer patients. The positive expression of annexin II was not related to the sex and age of the patients, while annexin II protein was expressed with tumor size, histological differentiation, TNM stage, lymph node metastasis and other clinical features were significantly correlated, the difference was statistically significant. The results suggest that annexin II protein is closely related to the malignant degree of gastric cancer.

Tumor metastasis is the most important malignant phenotype of the tumor and is the direct cause of this high mortality. Tumor metastasis is required in tumor cells themselves, host cells and extracellular matrix between the interaction can be completed, involves a series of complex processes and steps, including tumor cells from the primary tumor lesions, through the secretion of MMPs degradation of the extracellular matrix into the blood vessels or lymphatic vessels migrate to the distant, and then attack to the secondary organization or organ in the formation of metastases [10-14]. Therefore, the study of tumor metastasis for clinical diagnosis and treatment is important. To clarify whether annexin II in the process of gastric cancer metastasis play a role, in this study, annexin II-specific siRNA was used to inhibit annexin II expression in gastric cancer HGC-27 cells, after the expression of annexin II was reduced, gastric cancer HGC-27 cells migration, MMPs secretion and other capacity changes. The study found: in gastric cancer HGC-27 cells using annexin II-specific siRNA inhibited annexin II expression, gastric cancer cell migration, MMPs secretion and other capacity were reduced, suggesting that annexin II in the process of gastric cancer metastasis plays an important role.

In summary, annexin II in gastric cancer showed high expression, and the degree of differentiation of gastric cancer, TNM stage, lymph node metastasis and other clinical features are closely related, application of annexin II specific siRNA in gastric cancer HGC-27 cells inhibited annexin II expression, gastric cancer cell migration, MMPs secretion and other capacity are reduced, suggesting that annexin II plays an important role in the process of gastric cancer metastasis. The development and progression of gastric cancer is a complex multi-factor comprehensive results. At present, the etiology and pathogenesis of gastric cancer are more studied, but it is not clear. This study confirmed that annexin II was highly expressed in gastric cancer tissues and had the important role in gastric cancer metastasis. With the deepening of related research, annexin II gene expression, biological function and the role of progress in gastric cancer will be gradually clear, is expected to be used in the diagnosis and treatment of gastric cancer, predict the prognosis of markers and therapeutic targets.

COMMENTS

Background
Gastric cancer is one of the most common malignancies in my country, the first in the digestive tract malignant tumor, ranking the fourth in the world. Because of its symptoms hidden, the disease developed rapidly, when diagnosed in the late, the treatment effect is often poor, a serious threat to human health, but the early treatment of gastric cancer is good, 5 years after radical resection rate of up to 90% or more.

Research frontiers
Annexin II is a calcium-dependent phospholipid-binding protein, mainly in the form of monomer, dimer and tetramer, the study shows: Annexin II are highly expressed in liver cancer, breast cancer, colon cancer, lung cancer and other malignant tumors, and play an important role in the occurrence, development and infiltration of tumor.

Innovations and breakthroughs
The authors retrospectively analysed the expression of annexin II in 51 cases of gastric carcinoma and 24 cases of adjacent tissues, to investigate the relationship between the positive expression of annexin II and the invasion and metastasis of gastric cancer.

Applications
Annexin II in gastric cancer showed high expression, And the degree of
differentiation of gastric cancer, TNM stage, lymph node metastasis and other clinical features are closely related, suggesting that annexin II plays an important role in the process of gastric cancer metastasis.

**Terminology**

Annexins is a class of calcium-dependent phospholipid-binding proteins, they are widely present in the cell membrane, in the form of calcium-dependent reversible binding to cell membrane phospholipids, the latter determines Annexins specific biological functions.

**Peer-review**

This is an interesting study with great promise. AnnexinII was highly expressed in gastric cancer tissues and had the important role in the effect of promoting gastric cancer metastasis.

**REFERENCES**

1. Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. *World J Gastroenterol* 2016; 22: 2403-2414 [PMID: 26937129 DOI: 10.3748/wjg.v22.i8.2403]
2. El-Abd N, Fawzy A, Elbaz T, Handy S. Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma. *Tumour Biol* 2016; 37: 211-216 [PMID: 26189841 DOI: 10.1007/s13277-015-3524-x]
3. Jeon YR, Kim SY, Lee EJ, Kim YN, Noh DY, Park SY, Moon A. Identification of annexin II as a novel secretory biomarker for breast cancer. *Proteomics* 2013; 13: 3145-3156 [PMID: 24019232 DOI: 10.1002/pmic.201300127]
4. Sharma MR, Kołtowski L, Ownhey RT, Tuszyński GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. *Exp Mol Pathol* 2006; 81: 146-156 [PMID: 16643892 DOI: 10.1016/j.yexmp.2006.03.003]
5. Tristante E, Martínez-Camacho J, Jiménez S, Mora L, Carballo F, Martínez-Lacaci I, de Torre-Minguela C. Association of a characteristic membrane pattern of annexin A2 with high invasiveness and nodal status in colon adenocarcinoma. *Transl Res* 2015; 166: 196-206 [PMID: 25795236 DOI: 10.1016/j.trsl.2015.02.006]
6. Jia JW, Li KL, Wu JX, Guo SL. Clinical significance of annexin II expression in human non-small cell lung cancer. *Tumour Biol* 2013; 34: 1767-1771 [PMID: 23494179 DOI: 10.1007/s13277-013-0715-1]
7. Mirsaedi M, Gidfar S, Vu A, Schraufnagel D. Annexins family: insights into their functions and potential role in pathogenesis of sarcoidosis. *J Transl Med* 2016; 14: 89 [PMID: 27071553 DOI: 10.1186/s12967-016-0843-7]
8. Monastyrska K, Babychuk EB, Draeger A. The annexins: spatial and temporal coordination of signaling events during cellular stress. *Cell Mol Life Sci* 2009; 66: 2623-2642 [PMID: 19381436 DOI: 10.1007/s00018-009-0027-1]
9. Laohavisit A, Davies JM. Annexins. *New Phyto* 2011; 189: 40-53 [PMID: 21083562 DOI: 10.1111/j.1469-8137.2010.03533.x]
10. Bhowmick NA, Moses HL. Tumor-stroma interactions. *Curr Opin Genet Dev* 2005; 15: 97-101 [PMID: 15661539 DOI: 10.1016/j.gde.2004.12.003]
11. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. *Nat Med* 2006; 12: 895-904 [PMID: 16892035 DOI: 10.1038/nm1469]
12. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. *Nature* 2001; 411: 375-379 [PMID: 11357145 DOI: 10.1038/35077241]
13. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. *Nat Rev Cancer* 2003; 3: 362-374 [PMID: 12724734 DOI: 10.1038/nrc1075]
14. Porporato PE, Payen VL, Baselet B, Sonveaux P. Metabolic changes associated with tumor metastasis, part 2: Mitochondria, lipid and amino acid metabolism. *Cell Mol Life Sci* 2016; 73: 1549-1563 [PMID: 26640609 DOI: 10.1007/s00018-015-2100-2]
